Second, administration of an anti-CCR2 depleting antibody, which is presumed to target Ly6Chi monocytes selectively, ameliorates colitis and correlates with lower levels of IL6 and IL1β in colonic tissue [19]. This evidence concerns the gene CCR2 and colitis.